Bacil Pharma Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	15.56	4.04	-0.59	-1.02	-38.6
Depreciation & Amortization	-	0.01	0.02	0.03	0.04
Loss (Gain) From Sale of Assets	-	0.06	-	-	-
Other Operating Activities	-20.82	-0.29	-0.29	-0.3	-0.58
Change in Accounts Receivable	-11.8	-	-	-	-
Change in Accounts Payable	0.16	0.01	0.03	-0.1	-0
Change in Other Net Operating Assets	24.03	0.19	0.8	-0.09	-0.95
Operating Cash Flow	7.12	4.01	-0.03	-1.48	-40.09
Operating Cash Flow Growth	77.55%	-	-	-	-
Investment in Securities	-28.83	3.07	0.49	-1.46	37.55
Other Investing Activities	-	0.29	0.3	0.29	0.58
Investing Cash Flow	-23.82	3.37	0.78	-1.16	38.12
Short-Term Debt Issued	-	-	-	0.63	3.27
Total Debt Issued	-	-	-	0.63	3.27
Short-Term Debt Repaid	-	-6.82	-0.63	-	-
Total Debt Repaid	-	-6.82	-0.63	-	-
Net Debt Issued (Repaid)	-	-6.82	-0.63	0.63	3.27
Issuance of Common Stock	-	27.6	-	-	-
Other Financing Activities	-6.19	-	-	-	-
Financing Cash Flow	-6.19	20.78	-0.63	0.63	3.27
Net Cash Flow	-22.89	28.16	0.13	-2.01	1.31
Free Cash Flow	7.12	4.01	-0.03	-1.48	-40.09
Free Cash Flow Growth	77.55%	-	-	-	-
Free Cash Flow Per Share	0.51	0.64	-0.01	-0.25	-6.80
Levered Free Cash Flow	12.88	-2.07	-1.11	-1.17	-25.49
Unlevered Free Cash Flow	12.88	-2.07	-1.1	-1.16	-25.48
Change in Working Capital	12.38	0.19	0.84	-0.19	-0.95